RESEARCH DOSSIER
Insurance Target Market Negative Segmentation and Exclusions
Abstract. Insurance product governance requires the identification of populations whose objectives, circumstances, and protection needs are served by a proposed insurance contract. Negative target-market segmentation identifies populations for whom particular product characteristics create foreseeable incompatibility or inadequate value. This monograph examines the evidentiary basis, institutional design, distribution implications, and fairness constraints of that classification. A comparative analysis of European Union, United Kingdom, Australian, and selected United States regimes distinguishes manufacturer-level compatibility assessment from underwriting, contractual exclusions, and transaction-specific suitability. Supervisory reviews and behavioral insurance research inform an examination of the limits of revealed demand, aggregate claims metrics, and automated distribution filters. Illustrative numerical examples demonstrate the role of denominators, missing classifications, coverage utilization, and asymmetric costs of erroneous decisions. The analysis concludes that negative segmentation is justified by a demonstrable connection between product design and material consumer mismatch, subject to legal access requirements and ongoing review. Its institutional effectiveness depends on accurate distribution feedback, proportionate intervention, accessible alternatives where available, and remediation of realized harm. The study is a comparative documentary and analytical synthesis, not a new empirical estimate or an exhaustive survey of national law.
Keywords: insurance product governance; negative target market; product mismatch; insurance distribution; fair value; consumer protection; vulnerability; design and distribution obligations; market conduct; consumer outcomes
Introduction
The market for an insurance contract is constituted by the relationship between a contingent promise, the circumstances in which that promise becomes valuable, and the cost and practical conditions of obtaining it. A product can be financially sustainable for the insurer and still be poorly matched to the purposes of a particular population. The insurance arrangement may cover a different peril from the one that motivated purchase, require a deductible the policyholder cannot finance, or impose a waiting period that defeats the intended protection. Such incompatibilities belong to insurance governance because they arise before claims are made and can frequently be identified before distribution begins.
The subject of this dossier is the governance of product-to-population compatibility. Its primary questions are how empirical evidence can justify a negative market definition, how a protection-oriented boundary can become an unfair restriction on access, and what institutional response is appropriate when sales reach people outside the intended market. The unit of analysis is a specific product version, distribution context, and relevant customer population. A change in any element may invalidate a previously defensible classification.
The research uses purposive selection of primary legal texts and official regulatory materials, supplemented by selected academic research on insurance purchase behavior. The European Union and the United Kingdom provide insurance-specific governance rules; Australia provides an explicit statutory determination and distribution regime; selected United States materials demonstrate product-specific suitability and access constraints. These jurisdictions illustrate distinct mechanisms rather than a statistically representative global sample. The legal comparison is tied to the source versions identified in the bibliography, including the July 2026 Australian compilation and the August 2022 consolidated EU delegated regulation. The findings are analytical interpretations of those materials. Official study summaries and academic abstracts establish only the conclusions actually reported there. No firm-level or customer-level dataset has been independently collected or reanalyzed, and numerical cases below are hypothetical. No claim of original theoretical discovery is made.
Target Markets and Negative Segmentation
Product compatibility and institutional boundaries
The positive target market describes the group for which a product has been designed. A negative target market describes identifiable circumstances in which a material product feature conflicts with a likely need, objective, or relevant characteristic. Both descriptions depend on a specified contract. A person may be an appropriate prospective customer for one disability policy and an inappropriate prospective customer for another that uses a narrower definition of disability. The relevant question concerns the relation between the product and the person's circumstances.
The European Parliament and Council (2016) establish a manufacturer-level approval and review requirement in the Insurance Distribution Directive, article 25. Its scope excludes insurance of large risks under article 25(4). This limitation matters because the retail-target-market logic cannot simply be reported as an identical mandatory regime for every commercial insurance contract. Article 20 supplies a separate transaction-level demands-and-needs obligation in the applicable distribution context.
The European Commission (2017), in Delegated Regulation 2017/2358, requires the positive market to be identified at a level appropriate to product features and complexity. Article 5(2) permits identification of generally incompatible groups, particularly for insurance-based investment products, and contains an exception concerning products that consider sustainability factors. The negative-market provision is permissive in this text; it cannot be converted into a universal requirement to construct a formal blacklist for every insurance product. The consolidated provision, rather than the unamended 2017 wording, is the basis of this interpretation.
A target-market decision serves different purposes from a risk-classification decision. Underwriting determines whether a risk can be accepted and under what financial or contractual terms. Contractual exclusions delimit the insurer's contingent promise. Product governance examines whether the resulting offer is likely to serve the intended customer's purposes. Individual advice or suitability assessment evaluates a particular transaction. These activities interact but have different decision objects, evidence, and legal effects. Treating a governance classification as a new contractual defense to a valid claim would collapse the distinction between governance and the actual insurance promise.
Consider unemployment cover restricted to employees with permanent contracts. The contract's definition of qualifying employment determines whether an event is insured. If self-employed purchasers cannot meet the defining condition and seek income replacement during interruption, they present a strong case for negative segmentation of that particular product. The appropriate design response may be a different form of protection rather than the general exclusion of all self-employed people from income insurance. The example depends on hypothetical policy wording; actual definitions and legal restrictions vary.
The structure of a defensible market boundary
A useful classification describes the customer circumstance, the product feature generating incompatibility, the expected consequence, and the evidence supporting that connection. A population description such as young adults, low-income households, or residents of a particular postcode is insufficient by itself. It requires an explanation of why a specified feature creates material mismatch and why a more direct criterion or design adjustment would not solve the difficulty. A product marketed to people needing broad medical protection could, for example, leave a major intended exposure uninsured; the materiality of that mismatch depends on the actual benefit and the customer's needs.
The boundary is also different from the complement of the positive market. An unclassified or borderline person may have compatible needs that were not anticipated in the initial design. A strict negative category involves affirmative reasons for expected incompatibility. In ordinary governance analysis it is helpful to distinguish clearly compatible prospects, clearly incompatible prospects, and cases in which the available facts do not resolve compatibility. This is a descriptive distinction, not an assertion that any jurisdiction mandates a three-way classification.
The expected harm needs to be described at an appropriate level. A policy with a high deductible may still serve a wealthy policyholder who seeks protection only against catastrophic losses. The same deductible may frustrate a customer seeking affordable repair after modest damage. A minimum premium, an existing insurance contract, a geographic limitation, benefit cessation at a defined age, a waiting period, or an early surrender charge may generate mismatch in different ways. A single broad negative criterion that combines these mechanisms can conceal the actual cause and make remediation unnecessarily restrictive.
The UK framework illustrates why value must be included in the classification. The FCA's manufacturing rules in PROD 4.2 distinguish permission to identify generally incompatible groups from a specific obligation, for non-investment insurance, to identify groups unlikely to obtain the intended level of value. The rule therefore directs attention to both the product's protective function and the relationship between the package and its price. This distinction is especially important where a customer can claim under some circumstances yet the package remains a poor match for the stated objective.
Time and uncertainty in classification
An insurance product is a promise across time. A target-market statement should accordingly attend to circumstances at inception, changes during coverage, and the position at claim or renewal. A long-duration product can be appropriate at inception and become less useful as employment, dependents, health, assets, or other protective arrangements change. A properly accepted claim remains governed by the policy and applicable law; an evolving population classification cannot retrospectively rewrite contractual terms.
Uncertainty is intrinsic to insurance outcomes. A claims-free year establishes neither the absence of need at inception nor poor value. A high expected claims cost may indicate meaningful protection rather than inappropriate design. The governance case for negative segmentation is strongest where the relevant product feature makes benefit realization materially improbable or where the costs and restrictions are predictably incompatible with the consumer's objective. A responsible classification remains open to new evidence and is restricted to the decision for which it was justified.
Needs Testing and Mismatch Indicators
Evidence before distribution
Needs testing begins with the consumer risk and the protection objective. For a property policy, the relevant objective might be financing reconstruction after a severe loss; for credit protection it might be maintaining repayments during involuntary unemployment; for a life product it might be transferring financial resources to dependents upon death. Product testing examines how the proposed contract performs against those needs over the period of exposure, including realistic scenarios in which the customer seeks to exercise the promise.
Articles 5-6 of the EU delegated regulation and PROD 4.2.22-24 in the UK provide the legal grounding for such tests in their respective scopes. Their proportionality logic allows more complex or harmful products to require more detailed assessment. A scientific assessment should separate factual contract analysis from assumptions about behavior and financial circumstances: contract wording can establish an excluded event, while survey and claims information may inform how frequently the event matters to a population.
The evidence base can combine product wording, distribution interviews, customer research, representative usage scenarios, claim-event information, complaints and accessibility testing. Each source answers a different question. Contract analysis establishes features and restrictions. A survey may reveal demand or comprehension but depends on sampling and questionnaire quality. Claims files show realized outcomes among policyholders who remained insured and reported an event. Complaint files provide important signals but miss customers who never complain. Interviews reveal plausible mechanisms without necessarily estimating their population frequency.
A test must specifically challenge its own prior market definition. If an insurer consults only its current customer base, it cannot readily observe the needs of those screened out during acquisition. If it studies only claimants, it excludes policyholders who did not claim, either because no loss occurred or because the claim process was difficult. Pre-launch scenario testing can address some of this gap, while post-launch monitoring should collect additional information about inquiries, rejected applications, abandoned sales, and relevant accessibility barriers where lawful and proportionate.
Financial and contractual indicators
A useful starting point for testing is the expected payable benefit. In a stylized one-period contract with an eligible loss event probability p, covered loss amount L, deductible d, and maximum payable amount M, expected indemnity under those simplifying assumptions is p times min(M, max(L - d, 0)). In practice losses vary in size, eligibility and dependence; the expectation must integrate over those variations. Premium includes costs beyond expected indemnity, and the insurance benefit includes protection from uncertain losses, so this quantity is not a complete welfare measure.
Suppose two otherwise comparable groups face a 10 percent probability of a $2,000 covered event. A policy has a $500 deductible, no binding limit and a $250 annual premium. If group A can claim whenever that event occurs, the expected indemnity is $150. If a clearly specified contractual restriction means only 20 percent of those events are eligible in group B, the corresponding amount is $30. The expected indemnity-to-premium ratios are 60 percent and 12 percent respectively. These figures follow from the stated assumptions and do not establish observed market rates or a regulatory threshold. The disparity is a reason to investigate whether group B's actual objective is served, particularly when the purported insured event is central to the purchase.
A low ratio can coexist with valuable catastrophic protection; conversely, a comparatively high ratio can coexist with adverse customer outcomes through delays or unmet essential needs. Assessment should therefore examine the severity of uninsured residual losses, ability to fund deductibles, claims accessibility, uncertainty reduction, service quality, total price and coverage interactions. In bundled coverage it is necessary to identify the incremental protection after taking account of existing insurance and the applicable coordination or contribution terms. Apparent duplication does not always mean that the second policy lacks value.
An investment-linked insurance example raises additional dimensions. An early charge may materially undermine a purchaser's liquidity objective while remaining acceptable for a long-horizon purchaser with adequate reserves. Stress tests should include early exit, income loss and changes in market conditions. A deterministic illustration is useful for exposing a mechanism, but a recommendation about a real population requires an appropriate distribution of possible outcomes, realistic expenses, behavioral assumptions and validation against data.
Behavioral evidence and revealed demand
Consumer choices reveal behavior under a particular presentation of the alternatives. They do not independently establish that the chosen product meets a customer's protection needs. Cohen and Einav (2007), in Estimating Risk Preferences from Deductible Choice, report substantial heterogeneity in risk attitudes in an auto-insurance structural analysis. The full article uses deductible choices from one Israeli automobile insurer and estimates risk preferences jointly with claim risk. Its structural model relies on assumptions about claim frequency, information, and the absence of moral hazard. Heterogeneity within this specific setting supports the limited proposition that a uniform model of consumer preference can be misleading. Transferring its estimated parameters to other products, jurisdictions, or populations would require separate validation.
Sydnor's (2010) study of modest risks reports that homeowners in his data often chose low deductibles despite costs above expected benefit. The inference for governance is not that low-deductible products are inherently unsuitable: liquidity constraints and preferences for certainty may make them useful. The study instead illustrates that a price-to-expected-payout comparison and an observed choice are each incomplete evidence of product compatibility.
The FCA (2014a) general insurance add-ons study identified poor-value and unnecessary purchases in add-on distribution. Its companion behavioral experiment summary (FCA, 2014b) reports reduced effectiveness of shopping and comparison under an add-on mechanism. These findings establish a plausible distribution-related source of mismatch in the studied context, rather than a universal causal effect for every insurance bundle. A direct conclusion for governance is that sales conversion and renewal rates alone are insufficient measures of product fit. The sales process itself can influence the evidence used to validate the product.
Testing may therefore include plain-language comprehension tasks, comparison of product variants, accessibility checks, and scenarios in which the customer declines an optional benefit. The purpose is to establish whether the customer can understand the consequential limitations and act on the information. A disclosure click or signature is evidence that a procedural event occurred; it does not prove understanding, and it does not correct a fundamentally unsuitable product design.
Identification and statistical limitations
Evidence quality depends on precision, representativeness and causal interpretation. A discrepancy in outcomes across customer groups may be attributable to product design, channel selection, exposure differences, case mix, contract duration, reporting behavior, or sampling variation. An investigation should articulate the mechanism and examine alternatives. Cohorts should share a product version and observation window or be appropriately adjusted. Time to claim, time to cancellation, and maturity of settlement all affect comparisons. A model based on a small group or an unrepresentative historical period should communicate uncertainty rather than report precise but unstable classifications.
If a group is defined using a model trained on historical sales, the model may reproduce the previous channel's selection decisions. Where a governing law allows analysis of relevant characteristics, independent validation should examine false exclusions as well as missed mismatches. When data are insufficient, reasonable evidence gathering, narrower controls, human assessment, or alternative designs may be more appropriate than a sweeping negative label. The evidence supporting the decision and the evidence needed to revise it should be documented separately.
Distribution Controls and Exception Governance
The Australian Securities and Investments Commission (ASIC, 2024) elaborates the statutory distribution framework in its Regulatory Guide 274. Paragraphs 274.81–86 connect target-market specificity to observable attributes and recognize exclusion of consumer classes that cannot claim. Paragraphs 274.178–189 discuss information-based distribution controls, including screening questions, while rejecting reliance on consumer self-certification of target-market membership. Example 15 addresses annual insurance renewal and considers changes in circumstances and reasonable alternative arrangements. These examples show why the decision to interrupt a transaction and the decision to terminate existing coverage require separate analysis. The guide is supervisory interpretation; the legal obligations derive from the statute.
Manufacturer and distributor responsibilities
A product manufacturer's classification becomes consequential when it is translated into distribution. The manufacturer has knowledge of the design, contractual constraints and intended population. The distributor has information about the sales context and often the prospective customer's circumstances. These information sets are complementary. The FCA's distribution rules in PROD 4.3 expressly address understanding the product, its target market and, for relevant non-investment insurance, groups unlikely to receive fair value.
A distribution plan should communicate the features that cause incompatibility, the observations needed to identify relevant cases, the appropriate treatment of missing information, and the responsibilities for escalation and review. A marketing audience setting alone does not implement product oversight. Prospective customers can enter through search engines, comparison platforms, affiliates, brokers, call centers or renewal mechanisms that do not use identical information. Classification should be traceable to the product version and the channel conditions under which it was originally established.
If a product's intended use depends on an unfamiliar concept, the distributor should be able to explain it. If the selection criterion depends on a fact already known to the insurer, repeating unnecessary questions can add friction without improving decision quality. Where the product is complex and relevant information is unavailable, referral to trained staff or an appropriate advice process may help resolve the uncertainty. The distribution system should be proportionate to the likelihood and seriousness of detriment rather than uniformly intrusive.
Controls and exceptions
Controls can range from marketing restrictions and explanatory prompts to structured questions, human review or hard transaction stops. A hard stop is most defensible when a material incompatibility is directly observable, the applicable law allows the restriction, and the relevant decision can be made reliably. A customer whose objective cannot be met under the stated contract is a different case from a person whose evidence happens to be incomplete. In the latter situation a rigid block may create needless exclusion.
Exceptions require an explicit rationale. A distributor should distinguish an incorrectly classified person from a genuinely exceptional compatible use outside an anticipated population and from a sale that would remain harmful despite consent. The individual circumstances, the actual product feature, any permitted advice, and the authority for the decision belong in the record. A commercial override based solely on sales targets or commissions supplies no evidence of compatibility. Conversely, blocking every transaction outside an initially anticipated group can prevent access where the product would serve the consumer's objective.
A governance exception cannot authorize violation of statutory restrictions or contractually impossible coverage. Applicable law may limit or prohibit particular transaction types; the treatment of exceptions must therefore remain jurisdiction-specific. An exception decision also leaves intact any applicable point-of-sale duties. The presence of a market label does not establish the suitability of the specific transaction.
The control must work across intermediaries. A delegated distribution arrangement can specify product version identifiers, standardized mismatch reasons, reporting intervals, minimum data quality and escalation contacts. Audit sampling should examine both approved transactions and rejected or abandoned cases. The former detects adverse sales; the latter detects access lost through misclassification, confusing journeys or excessive friction. Unexplained differences between channels justify investigation without automatically establishing misconduct.
Automated distribution and proxy risk
Automated decision systems can apply product criteria consistently, but design errors can scale rapidly. A proxy such as postcode may mix an insured risk characteristic with socioeconomic or demographic circumstances; it can also be substantially less accurate than asking a direct, relevant question about the risk or the protection need. A predictive score is a statistical output, not a legal authorization to restrict access. The analyst must know what outcome the score predicts, whose data were used, which error rates matter, and how the decision is reviewed.
For an illustrative classification with independently reviewed reference labels, suppose 100 of 1,000 applicants present a material mismatch. A screening process correctly flags 80 of those 100 and incorrectly flags 90 of the other 900. Its sensitivity is 80 percent, specificity 90 percent, and positive predictive value 80/170, approximately 47.1 percent. Twenty incompatible applicants remain unflagged, while 90 compatible applicants would be blocked if all flags automatically resulted in denial. The example shows why a high overall accuracy of 89 percent does not settle the choice of intervention. The severity and reversibility of both types of error, prevalence in the relevant population, and legal restrictions determine whether a prompt, manual assessment, or block is proportionate.
The reference classification in real data is itself uncertain. A rejected applicant's eventual coverage needs may be unknown, and a successful sale may later prove mismatched. Continuous review should distinguish algorithmic prediction errors from ambiguity in the governing product criteria. A model designed to predict claim cost should not silently substitute for a model of consumer benefit or access.
Fairness and Consumer Vulnerability
The international supervisory perspective is developed by the International Association of Insurance Supervisors (IAIS, 2025) in its fair treatment application paper. Section 4.2.1 recommends attention to different needs within an intended customer group, explicit exclusion criteria tied to product attributes, and differentiated scenario testing. The paper also recognizes risk-based pricing and insurer autonomy. As guidance supporting ICP 19, it adds no new binding requirements. Its practical importance for negative segmentation lies in combining two inquiries: whether particular buyers can benefit from the product, and whether changes to its design or distribution could responsibly extend access.
Compatibility and nondiscrimination
The ethical justification for negative segmentation rests on preventing foreseeable harm associated with a particular offer. That justification becomes weak when the same mechanism could be addressed through less restrictive product design or accessible distribution. The legal justification is independent: a plausible consumer-protection rationale does not displace a statutory access right or discrimination prohibition.
The CJEU's 2011 Test-Achats judgment invalidated the derogation in article 5(2) of Directive 2004/113/EC from 21 December 2012. Its specific context concerns sex-based differences in individual premiums and benefits. The decision illustrates an important distinction between predictive relevance and legal permissibility. It does not establish a uniform ban on all demographic analysis in every insurance task or jurisdiction.
The United States Marketplace health-insurance example provides another concrete access constraint. The federal Marketplace coverage explanation (CMS, n.d.) states that Marketplace plans must cover pre-existing conditions and distinguishes grandfathered plans. The finding applies to that specified class of health coverage. A governance policy that excludes people solely because they have a pre-existing condition from such a plan would conflict with the access and coverage obligation as described by the federal source. It is not scientifically legitimate to generalize this selected rule to all life, disability or other insurance contracts.
The analysis of any real criterion should identify the applicable legal regime, the affected population, the product-specific mechanism, legitimate objectives and feasible alternatives. Outcome disparity can warrant investigation even where there is no explicit classification using a protected characteristic; at the same time, disparity alone does not establish the precise legal test or the underlying cause. Those questions depend on jurisdiction, product and evidence.
Vulnerability as an outcome consideration
Vulnerability can arise through circumstances that influence a person's ability to understand, access or use insurance. FCA (2021) guidance on vulnerable customers directs firms to understand how vulnerability affects needs and outcomes. In governance analysis the existence of vulnerability should prompt examination of what support or design change would improve the product's performance. It should not automatically serve as a negative-market criterion.
A person with impaired hearing may need an alternative communication format rather than exclusion from a policy sold through telephone channels. A customer with low financial resilience may benefit strongly from a policy that prevents catastrophic loss while facing difficulty with a large deductible or recurring payment. A person experiencing bereavement may need time and clarity in decision-making. The relevant restriction concerns the feature that impedes protection. Accessible communication, flexible payment where viable, reasonable accommodation and assisted channels can preserve access without weakening the substantive compatibility test.
Data on vulnerability can be especially sensitive. Collecting information simply because it might correlate with poor outcomes creates privacy and governance risks. A proportionate process should identify the information genuinely needed for the decision, use appropriate access controls and retention periods, and observe applicable privacy and equality rules. An operational record can sometimes describe the required support rather than infer or store an underlying medical condition. Assessment of legal permission to collect and process particular sensitive attributes requires the relevant privacy law and facts; this dossier does not supply that determination.
Affordability, exclusion and redesign
Affordability and value should be examined separately. A product may offer substantial protective value but remain unaffordable for some consumers. A cheap product can offer little usable protection. Negative segmentation directed at unaffordability may prevent excessive commitments, but a broad low-income filter can deprive people of valuable protection without addressing price or payment structure. The scientific question is which feature causes an unacceptable risk of poor outcomes, and whether that feature can be modified.
A redesign can change limits, deductibles, exclusions, premium structure, options, or distribution support. Such changes entail actuarial and operational costs, and broader coverage must remain financially sustainable. There can be real trade-offs between coverage breadth, affordability, adverse selection and risk-pool viability. The governance analysis should make those trade-offs visible instead of assigning all responsibility to the customer. Where no viable design serves a need, the resulting protection gap should be recognized; claims of universally available substitute insurance require separate market evidence.
The fairness of a product boundary ultimately depends on what happens on both sides. Customers admitted to a target market should receive the protection and service that justified inclusion. Customers excluded should receive an accurate explanation where appropriate and lawful, and should not be misled into believing that their entire risk category is uninsurable. Review and correction of an incorrect classification are particularly important where the decision creates substantial financial exposure.
Monitoring, Distribution Feedback and Remediation
Measurement and denominators
The target market is a revisable population statement. It must be assessed against actual distribution and outcomes, not merely approved once. Article 7 of the EU delegated regulation is particularly relevant to monitoring whether products remain compatible with their intended markets and to corrective action when adverse circumstances arise. The FCA (2026) mutual life insurer review reports the importance of clear target-market descriptions, identifying groups unlikely to receive fair value, and effective outcome monitoring in pure protection. As a supervisory review of selected firms, it cannot establish sector-wide prevalence.
A monitoring record should distinguish positive, negative, outside-but-not-demonstrably-negative and unclassified transactions where the product governance framework uses such distinctions. Let N be all sales in a specified product cohort and observation window, n the number known to fall within a specified negative category, and u the number with insufficient data to determine category membership. The observed minimum proportion of negative-market sales is n/N. If all unclassified cases could belong to the negative category, the maximum consistent with the information is (n+u)/N. These bounds make no assumption about the unknown cases.
Suppose 10,000 sales include 200 identified negative-market transactions and 1,000 unclassified transactions, with all others classified as outside the negative category. The observed lower bound is 2 percent; the corresponding upper bound is 12 percent. Among the 9,000 classified sales the observed proportion is approximately 2.22 percent. Reporting 2.22 percent without the missing fraction would conceal a material uncertainty. The bounds are simple logical limits under the stated classification assumptions; they are not confidence intervals or estimates of actual incidence.
A dashboard should identify the denominator for every metric. Claim acceptance rates concern reported and adjudicated claims; a frequency of accepted claims per exposure period concerns insured exposure; early cancellation concerns the population at risk of cancellation over a specified duration. Combining these without adjustment creates misleading comparisons. If a contract has a waiting period, apparent claim absence in early months may reflect that feature, incomplete observation, or both. The data should allow these distinctions to be investigated.
Complaints per thousand policies, claim rejection reasons, cancellations, payment arrears, lapse and renewal behavior, benefit utilization, and channel-specific negative-market sales can all contribute. Each should be interpreted against product type, time window, severity and expected exposure. Low complaints may reflect good outcomes or an inaccessible complaint process. A low claim rate may indicate infrequent events or poorly aligned cover. A high exception rate may reflect a defective definition or commercial overrides. No single statistic answers the governance question.
Triggering investigation and correction
Review triggers should respond to both changes in the product and credible signals from the market: changed policy terms, changes in price or distribution incentives, recurring complaints about the same exclusion, a material cluster of mismatched transactions, unexpected cancellation patterns, or a significant change in the customer population. A single severe case can justify urgent investigation without waiting for statistical significance. Conversely, routine low-severity variation may be handled through scheduled review and adjusted sampling. Thresholds need explicit justification; universal numerical triggers are neither established by this analysis nor supported by the selected sources.
An illustrative distribution comparison helps distinguish volume from risk. Channel A sells 8,000 policies and produces 80 verified negative-market transactions; channel B sells 2,000 policies and produces 100. The respective observed rates are 1 percent and 5 percent, and the combined rate is 1.8 percent. Channel B deserves focused investigation, while channel A still accounts for 80 potentially problematic transactions. A rate alone cannot determine the amount of detriment. Investigators should review case severity, data completeness and differences in eligible consumer composition.
When a mismatch is detected, the response depends on cause and scope. A wrongly configured filter may require a software correction and reassessment of blocked applications. A misleading sales script may require correction, retraining, review of affected customers and changes to incentive arrangements. A product that inherently fails its intended objective may need redesign or suspension of relevant distribution. Retrospective remediation can involve a reassessment of the policyholder's position, appropriate communication, correction of records, restitution or another remedy where the governing law, contract and facts support it. A monitoring flag by itself does not establish the remedy owed to an individual.
Evidence of effectiveness must be preserved after the intervention. Comparing rates before and after introducing a control is helpful but may be confounded by changes in population, product, seasonality or channel volume. An apparent improvement caused by excluding more compatible customers would be an undesirable result. Reassessment should therefore track both consumer outcomes and access indicators. Affected cohorts, time windows, documented decisions, and the scope of remediation should be clear enough to reconstruct the sequence.
Reporting and supervisory feedback
The Australian statutory regime illustrates the importance of separating internal review triggers from legally defined reporting events. Sections 994F and 994G of the Corporations Act 2001 address reporting of significant inconsistent dealings, with the applicable exceptions and statutory time limits. A breach analysis must rely on the precise legal definitions rather than a firm's internal dashboard label. The statute also imposes review and distribution obligations in specified circumstances. The wider analytical implication is that classification and reporting data need provenance: a supervisory notification must be traceable to an actual dealing, the TMD version, the information available, and the reason for inconsistency.
At a supervisory level, EIOPA's (2026) POG peer-review follow-up describes progress toward operational, risk-oriented product supervision among national authorities. The follow-up examined manufacturer oversight of insurance-based investment products through national authorities' documentary reporting and covered the period from August 2023 to June 2025. Of 110 recommended actions addressed to 30 authorities, 68 were assessed as fulfilled, 29 as partially fulfilled, and 13 as unfulfilled. The unit of observation is the recommended supervisory action; these counts cannot be interpreted as frequencies of incompatible insurance sales or measures of consumer welfare. It supports the institutional interpretation that documented product approval must be accompanied by scrutiny of the way the product performs when distributed.
Comparative Product Oversight Models
European Union and United Kingdom
The EU model connects product approval, compatible target markets, appropriate distribution, and ongoing review through the IDD and delegated rules. Its negative-market identification clause is optional within the stated conditions; the broader obligation to identify and serve an appropriate positive market is central. The difference between group-level compatibility and individual demands and needs is preserved. Practical consequences therefore depend on both the particular product and national implementation and supervision.
The UK framework contains insurance-specific manufacturing and distribution rules and has an additional fair-value emphasis for non-investment insurance. Its rule identifying groups unlikely to receive intended value supplies a more explicit subgroup-level obligation than a general permission to designate incompatible groups. Legal comparison should use the actual provisions rather than infer that terminology shared with the EU necessarily has identical scope after the UK's departure from the EU. The study does not equate PROD 4 with every Consumer Duty provision or claim that all obligations apply to all contracts.
Australia
Australia's Part 7.8A of the Corporations Act uses a written target market determination for financial products falling within its scope. Section 994B contains the appropriateness condition connecting distribution conditions and likely customer objectives, financial situation and needs; the determination is made publicly available. Section 994E sets reasonable-steps obligations and distinguishes those obligations from a guarantee that every acquisition is within the market. Sections 994C and 994F-G cover review and reporting mechanisms; section 994J establishes stop-order powers subject to its conditions.
This framework therefore supplies an explicit institution-level structure for evaluating the design as well as the distribution process. A sale inconsistent with a determination should not be treated as identical to a failure to take reasonable steps or as automatically constituting a significant reportable dealing. These are analytically and legally distinct questions. The applicability of the regime to a specific insurance product depends on statutory scope and exceptions. Personal advice and other excluded conduct require careful treatment under the relevant provisions.
Selected United States arrangements
The United States material illustrates a different regulatory configuration through product-specific rules and state implementation. The NAIC's annuity best-interest standard summary describes the 2020 revisions to Model #275, including requirements concerning consumer interests in recommendations and insurer supervision. A model regulation is not by itself an enacted law in every state. Its relevance here is the supervision of annuity recommendations and conflicts, not the existence of a universal American negative-target-market determination.
For Marketplace health plans, the federal access rule illustrates how legal eligibility and permitted contractual restrictions can constrain insurer discretion. The resulting architecture is not adequately captured by transplanting either the EU's negative-market terminology or the Australian TMD mechanism. A valid cross-jurisdictional comparison identifies the regulated product, institutional actor, operative duty, status of the legal instrument, relevant exception, and remedy.
Comparative synthesis
| Dimension | European Union | United Kingdom | Australia | Selected United States |
|---|---|---|---|---|
| Governing instrument examined | IDD and delegated POG regulation | FCA PROD 4.2 and 4.3 | Corporations Act Part 7.8A | NAIC Model #275 summary; federal Marketplace explanation |
| Product-population assessment | Manufacturer approval and compatible group | Manufacturer approval with non-investment insurance value groups | Written TMD for in-scope products | Product-specific recommendation and access requirements |
| Negative boundary | Permissive clause with specified exception | Generally incompatible groups; specific value-group obligation | Appropriateness and distribution consistency | No general equivalent established by sources examined |
| Feedback | Manufacturer review and distribution arrangements | Manufacturer and distributor controls | Review triggers and significant-dealing notification | Insurer annuity supervision; specific access constraints |
| Scope limitation | Large-risk exception to IDD article 25 | Product and rule applicability | Statutory exceptions and excluded conduct | State adoption and federal product scope |
The table is a functional comparison, not a ranking of regulatory efficacy. The legal sources do not establish comparable enforcement intensity, compliance costs, or causal effects on consumer welfare across jurisdictions. Those outcomes would require systematically harmonized observational or experimental evidence. The comparison instead shows that product governance can be institutionalized through different legal objects: manufacturer approval, subgroup value assessment, a public market determination, or recommendation and access restrictions.
Analytical contribution and research boundaries
The comparative and behavioral materials support three interrelated conclusions. First, negative segmentation has an evidentiary structure. It requires a specified contract, a specified customer objective or circumstance, a causal account of foreseeable incompatibility, and a defensible assessment of materiality. Historical purchasing patterns supply useful evidence but cannot replace this account. Second, the boundary should be evaluated through two directions of error: protective failures that allow harmful sales and access failures that wrongly exclude compatible customers. Third, governance must provide a feedback relation between decisions and outcomes; the population affected by an exclusion cannot disappear from the institution's evidence merely because the product was never sold to it.
These conclusions are an analytical synthesis rather than a new doctrine. They are derived from distinctions already present in product-governance requirements, the limited behavioral research examined, and the logical consequences of uncertainty in classification. The illustrative calculations demonstrate measurement problems without asserting market prevalence. Operational decisions remain subject to local law and validated product-specific data. The research does not determine optimal universal thresholds, establish quantitative effects of a regulatory regime, or provide individual insurance, legal, actuarial or financial advice.
Conclusion
Insurance target-market negative segmentation is an instrument for controlling foreseeable mismatch between an insurance offer and the objectives and circumstances of prospective customers. Its foundation is the relationship between the actual contract, the probable circumstances in which protection is needed, and the price and practical conditions of accessing that protection. An exclusion is scientifically defensible when the incompatibility is material, supported by evidence and expressed through a criterion directly relevant to the product.
A robust evidentiary assessment combines contractual analysis, consumer research, scenario testing, and observation of realized outcomes. It distinguishes sales from suitability, claims frequency from value, missing information from verified mismatch, and predictive association from legally permissible classification. The economic value of insurance includes the transfer of uncertainty, so low expected indemnity alone does not demonstrate poor value. Likewise, observed purchase decisions cannot establish appropriate distribution where the channel itself has influenced choice.
The comparison identifies meaningful differences between jurisdictions. EU law permits explicit negative-market designation within its stated scope and conditions; UK insurance-specific rules include identification of groups unlikely to receive intended value in non-investment insurance; Australia's TMD regime connects design, distribution consistency, review, and reporting; selected US rules illustrate product-specific suitability and access constraints. The legal effect of an exclusion remains dependent on its jurisdiction and product. These distinctions provide the foundation for comparative research without artificially treating different regulatory instruments as equivalent.
Effective governance corrects both harmful admission and erroneous exclusion. A distribution system should differentiate established mismatch from unresolved information, permit case-specific review where lawfully appropriate, and preserve evidence of rejected as well as completed transactions. When adverse outcomes emerge, investigation should identify the source of failure and distinguish design correction, distribution correction, individual remediation, and statutory reporting. Changes should be evaluated through both consumer outcomes and meaningful access.
The institutional purpose of a negative target market is achieved when the identified boundary improves the relationship between insurance promises and the protection customers can actually use. Such a boundary is necessarily contingent on evidence, product version and applicable law. Continuous review, clear responsibilities, accurate information exchange and proportionate corrective action make the classification a working instrument of market conduct rather than a static marketing description.
References
European Parliament and Council (2016). Directive (EU) 2016/97 of 20 January 2016 on insurance distribution (recast), OJ L 26, 2 February 2016, pp. 19-59. Consolidated 9 January 2024, arts. 20, 25, 30. Source.
European Commission (2017). Commission Delegated Regulation (EU) 2017/2358 of 21 September 2017 supplementing Directive (EU) 2016/97 with regard to product oversight and governance requirements for insurance undertakings and insurance distributors. OJ L 341, 20 December 2017, pp. 1-7. Consolidated 2 August 2022, arts. 5-8, 10-11. Source.
Financial Conduct Authority (FCA) (2026). FCA Handbook, PROD 4.2: Manufacture of insurance products. Rules and guidance, including PROD 4.2.16-24 and 4.2.15A; cited provisions effective 2018-2024. Source.
Financial Conduct Authority (FCA) (2025). FCA Handbook, PROD 4.3: Distribution of insurance products. Section last updated 9 December 2025; PROD 4.3.1-4. Source.
Financial Conduct Authority (FCA) (2021). FG21/1: Guidance for firms on the fair treatment of vulnerable customers. Official publication page, February 2021. Source.
Financial Conduct Authority (FCA) (2014a). General insurance add-ons market study. Final findings, 24 July 2014; page updated 1 April 2016. Source.
Financial Conduct Authority (FCA) (2014b). Occasional Paper No. 3: How does selling insurance as an add-on affect consumer decisions? Official publication summary. Source.
Financial Conduct Authority (FCA) (2026). Multi-firm review of customer outcomes delivered by smaller mutual life insurers. Official supervisory review. Source.
European Insurance and Occupational Pensions Authority (EIOPA) (2026). Follow-up Report to EIOPA's Peer Review on Product Oversight and Governance (POG). EIOPA-BoS-26-249, 30 June 2026. Full report. Source.
Commonwealth of Australia (2001). Corporations Act 2001 (Cth), No. 50, compilation no. 147, 1 July 2026, vol. 4, Part 7.8A, ss. 994B-994J. Source.
National Association of Insurance Commissioners (NAIC) (n.d.). Annuity Suitability and Best Interest Standard. Insurance Topics; description of Model #275 revisions adopted February 2020, accessed 19 November 2026. Source.
Court of Justice of the European Union (CJEU) (2011). Association belge des Consommateurs Test-Achats ASBL and Others v Conseil des ministres, Case C-236/09, judgment of 1 March 2011, ECLI:EU:C:2011:100. Source.
Centers for Medicare & Medicaid Services (CMS) (n.d.). Coverage for pre-existing conditions. HealthCare.gov. Accessed 19 November 2026. Source.
Cohen, Alma, and Liran Einav (2007). Estimating Risk Preferences from Deductible Choice. American Economic Review 97(3), 745-788. DOI: 10.1257/aer.97.3.745. Source.
Sydnor, Justin (2010). (Over)insuring Modest Risks. American Economic Journal: Applied Economics 2(4), 177-199. DOI: 10.1257/app.2.4.177. Source.
Australian Securities and Investments Commission (ASIC) (2024). Regulatory Guide 274: Product design and distribution obligations. September 2024, paragraphs 274.81–86, 274.178–189 and Example 15. Source.
International Association of Insurance Supervisors (IAIS) (2025). Application Paper on Fair Treatment of a Wide Range of Consumers. July 2025, executive summary and section 4.2.1. Source.